A detailed history of Ensign Peak Advisors, Inc transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Ensign Peak Advisors, Inc holds 28,464 shares of CRSP stock, worth $1.18 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
28,464
Previous 28,464 -0.0%
Holding current value
$1.18 Million
Previous $1.54 Million 13.01%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$60.67 - $89.12 $87,122 - $127,976
-1,436 Reduced 4.8%
28,464 $1.94 Million
Q2 2023

Aug 14, 2023

BUY
$43.47 - $67.77 $95,634 - $149,094
2,200 Added 7.94%
29,900 $1.68 Million
Q1 2023

May 15, 2023

BUY
$41.0 - $56.12 $1.14 Million - $1.55 Million
27,700 New
27,700 $1.25 Million
Q2 2022

Aug 12, 2022

BUY
$43.23 - $73.83 $1.61 Million - $2.74 Million
37,169 New
37,169 $2.26 Million

Others Institutions Holding CRSP

About CRISPR Therapeutics AG


  • Ticker CRSP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,009,296
  • Market Cap $3.23B
  • Description
  • CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....
More about CRSP
Track This Portfolio

Track Ensign Peak Advisors, Inc Portfolio

Follow Ensign Peak Advisors, Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ensign Peak Advisors, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ensign Peak Advisors, Inc with notifications on news.